5,7-Dihydroxy-2-(2,3,4-trihydroxyphenyl)chromen-4-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 5,7-Dihydroxy-2-(2,3,4-trihydroxyphenyl)chromen-4-one
• 化学式: C₁₅H₁₀O₇
• 分子量: 302.23
• InChiKey: MIRFNZKXFFLSRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  127
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY
  申请人：OSTEONEUROGEN INC.

  公开号：US20170239211A1

  公开（公告）日：2017-08-24

  A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

  一种药物组合物包含化学式1的咖啡酮衍生物和一种药用可接受的盐作为活性成分，从而有效抑制EMT的激活，从而使得能够有效抑制由于EMT激活而导致的器官或组织纤维化引起的疾病。
• Method and system for effecting changes in pigmented tissue
  申请人：Moazed Kambiz Thomas

  公开号：US20120207809A1

  公开（公告）日：2012-08-16

  Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are compositions for lightening or darkening the pigmented tissues or treating a pigmented tissue disease.

  本文描述了一种快速和可持续改变虹膜基质黑素细胞中黑色素含量的方法和系统，从而改变眼睛的颜色。还描述了用于使色素组织变浅或变深或治疗色素组织疾病的组合物。
• Use of eupatilin as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity
  申请人：OSTEONEUROGEN INC.

  公开号：US10744114B2

  公开（公告）日：2020-08-18

  A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

  一种药物组合物含有化学式 1 的铬酮衍生物和药学上可接受的盐作为活性成分，从而有效抑制 EMT 的活化，从而能够有效抑制体内器官或组织因 EMT 活化而纤维化引起的疾病。
• Use of chromone derivative as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity
  申请人：OSTEONEUROGEN INC.

  公开号：US10744113B2

  公开（公告）日：2020-08-18

  A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

  一种药物组合物含有化学式 1 的铬酮衍生物和药学上可接受的盐作为活性成分，从而有效抑制 EMT 的活化，从而能够有效抑制体内器官或组织因 EMT 活化而纤维化引起的疾病。
• Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients
  申请人：KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

  公开号：US10765128B2

  公开（公告）日：2020-09-08

  A composition for prevention or treatment of metabolic syndrome or for antioxidation includes black soybean leaf extracts and flavonol glycoside compounds isolated thereof as active ingredients. It has been confirmed that the black soybean leaf extracts and the flavonol glycoside compounds isolated thereof effectively inhibit α-glucosidase activity; LDL oxidation and DDP-4; have excellent DPPH radical scavenging activity; inhibitory activity of reactive oxygen species (ROS) accumulation; effectively promote insulin secretion; regulate the expression of major genes; have an excellent ability to reduce a waist/hip circumference ratio; decrease the concentrations of plasma free fatty acid and plasma triglyceride; increase the concentration of plasma HDL-cholesterol; decrease an atherogenic index; increase erythrocyte catalase, SOD and GR activities; decrease erythrocyte lipid peroxide TBARS; decrease the concentrations of inflammatory cytokines MCP-1 and PAI-1, and resistin; and increase the concentration of plasma adiponectin.

  一种用于预防或治疗代谢综合征或抗氧化的组合物包括作为活性成分的黑大豆叶提取物及其分离的黄酮醇苷化合物。经证实，黑豆叶提取物及其分离出的黄酮醇苷化合物能有效抑制α-葡萄糖苷酶活性、低密度脂蛋白氧化和DDP-4；具有极佳的DPPH自由基清除活性；抑制活性氧（ROS）积累；有效促进胰岛素分泌；调节主要基因的表达；具有极佳的降低腰围/臀围比的能力；降低血浆游离脂肪酸和血浆甘油三酯的浓度；提高血浆高密度脂蛋白胆固醇的浓度；降低动脉粥样硬化指数；提高红细胞过氧化氢酶、SOD 和 GR 活性；降低红细胞过氧化脂质 TBARS；降低炎症细胞因子 MCP-1 和 PAI-1 以及抵抗素的浓度；提高血浆脂肪连通素的浓度。